Press Releases
Patent Litigator Mark Remus Presents on IPR Strategy at CPhI's 6th Annual Pharma IPR Conference
March 07, 2017

CHICAGO—Mark Remus, a shareholder and patent litigator at intellectual property law firm Brinks Gilson & Lione, presented “The Strategic Use of IPRs to Challenge Pharmaceutical Patents” at CPhI’s 6th Annual Pharma IPR Conference in Mumbai, India, on March 1, 2017.

Remus discussed using inter partes review (IPR) proceedings before the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board as leverage to encourage early settlement of patent infringement lawsuits and save litigation costs. He also weighed the pros and cons of IPRs versus opposition procedures before the European Patent Office, and reviewed recent changes to the law with regard to IPR.

Remus is a seasoned trial lawyer with extensive experience in pharmaceutical litigation under the Hatch-Waxman Act. He advises clients on a wide range of drug products and technologies, including new chemical entities, complex formulations, polymorphs, methods of treatment, and extended release formulations. Remus is also experienced in FDA practice and strategy related to generic pharmaceutical products, including controlled correspondence, citizen petitions, suitability petitions, and labeling carve-outs. He is a frequent speaker and author on current topics in patent law.

Brinks Gilson & Lione is a Gold Partner of CPhI Pharma IPR India 2017. The conference is a forum for more than 250 thought leaders from leading Indian pharmaceutical companies and global law firms to discuss the prevailing issues faced by the pharmaceutical industry in India.

More information at

Brinks Gilson & Lione

Celebrating its centennial year in 2017, Brinks Gilson & Lione is one of the largest intellectual property law firms in the US, and helps clients around the world to protect and enforce their intellectual property rights. Our more than 140 lawyers, patent agents and scientific advisors assist clients in all aspects of patent, trademark, unfair competition, trade secret, and copyright law. Brinks attorneys provide informed counsel with respect to innovations in a range of complex and valuable technologies, including pharmaceuticals, chemicals, bioengineering, industrial manufacturing, electronics and software, and medical devices. More information is at

Forward Thinkers